Smarter Cancer Care
Genomic Health delivers the promise and value of precision medicine
with the Oncotype IQ portfolio of genomic tests.
What's New

Announcement

Updated Medicare Coverage

The Oncotype DX Genomic Prostate Score test is now covered by Medicare for favorable intermediate-risk prostate cancer.

Real People.
Real Results.
When Amy was diagnosed with breast cancer, she was scared. Her Oncotype DX Breast DCIS Score result made her feel in control.
Healthcare Savings
Ineffective cancer treatments exact human as well financial costs. Oncotype IQ tests have saved more than $3.5 billion in the US.
Practice Tools

The Eighth Edition AJCC Staging Manual will go into effect in 2018, and it will change staging for T1-2 N0 M0 breast cancer patients.

Latest TAILORx Data
After 5 years, 95% of women with a low Oncotype DX Breast Recurrence Score result were recurrence-free with hormone therapy alone.

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™